Fizazi K, Culine S
Département de médecine, Institut Gustave-Roussy, Villejuif.
Bull Cancer. 1998 Jul;85(7):609-17.
Carcinomas of unknown primary site are microscopically confirmed metastatic epithelial malignancies with no identified primary site at the onset of treatment. Their incidence is about 5% among all cancer patients. They represent a group of heterogeneous tumors with low chemosensitivity and poor outcome: the overall median survival is about 6 months. The search for primary tumor should be limited to the identification of subgroups of patients requiring specific therapies: 1) patients with cervical lymph nodes containing squamous carcinoma; 2) women with axillary lymph nodes containing adenocarcinoma; 3) women with peritoneal adenocarcinomatosis; 4) young men with poorly differentiated carcinoma of the midline; 5) patients with neuroendocrine metastasis. Other patients are to be managed with symptomatic procedures and possibly chemotherapy. Simple prognostic factors such as performance status, histology and serum levels of alkaline phosphatase may help the physician to select treatment strategies with the aim of preserving an optimal quality of life.
原发部位不明的癌是经显微镜确诊的转移性上皮恶性肿瘤,在治疗开始时未发现原发部位。其发病率在所有癌症患者中约为5%。它们代表一组异质性肿瘤,化疗敏感性低且预后差:总体中位生存期约为6个月。对原发肿瘤的查找应限于识别需要特定治疗的患者亚组:1)宫颈淋巴结有鳞状癌的患者;2)腋窝淋巴结有腺癌的女性;3)有腹膜腺癌病的女性;4)中线低分化癌的年轻男性;5)有神经内分泌转移的患者。其他患者应采用对症治疗措施,可能还需化疗。诸如体能状态、组织学和血清碱性磷酸酶水平等简单的预后因素可帮助医生选择治疗策略,以维持最佳生活质量。